News & Events
Cellaria Inc. Introduces A New Generation Of Cell Line Models For Pancreatic Cancer Paving The Way For Better Treatment
Delivering stable, authenticated, patient-specific cell platforms for more reproducible, clinically relevant research. 09/29/2020 WAKEFIELD, MA: Cellaria Inc (Wakefield, MA, USA), a scientific innovator with breakthrough tools for cancer research, has introduced three read more
Data Demonstrating Power of Metastatic Niche and Patient-Specific Models in Oncology Drug Screening Studies Presented at 2020 AACR Virtual Annual Meeting II
First presentation of data using Cellaria’s proprietary patient-specific models of the tumor microenvironment used to study tumor growth, metastasis.
06/24/2020 WAKEFIELD, MA: Cellaria announces today it is presenting data on the value of modeling the metastatic niche, and the benefits of using patient-derived cancer cell models, mesenchymal stem cells (MSCs), and optimization of oxygen level and extracellular matrix (ECM) to study antitumor drug response, personalized therapy, and disease mechanisms. The data, featured in a poster at 2020 AACR Annual Meeting II, results from Cellaria’s spheroid system using five cancer cell models (pancreatic, lung adenocarcinoma, colon adenocarcinoma, endometrioid ovarian and high-grade serous carcinoma). With this 3D system, Cellaria is addressing an unmet need to improve predictions of the safety and efficacy of new drugs in preclinical testing and clinical trials.
By using patient-specific cell models, translational scientists are able to go beyond traditional cell lines, to address the complexity and individuality of the disease and identify treatments that better meet the needs of each patient. Specificity in cell models enables researchers to derive the answers they need earlier in the drug development life cycle and with a continuous, direct connection to the patient.
“This data demonstrates the power of using patient specific cell models in a 3D format to model the tumor microenvironment and gain more actionable information from drug screening studies” comments David Deems, CEO, Cellaria Inc. “By using specific model patient populations that maintain their heterogeneity and individuality, users can test targets on our highly characterized cell models and select the mutation profile that is most important to their research.”
About Cellaria Inc.
Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.
Partnership targets broader availability of new models and tools for cancer research
Cambridge, Mass. and Natick, Mass., May 02, 2018 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the formation of a strategic partnership with SBH Sciences (SBH). The companies will collaborate to evaluate drug response using Cellaria’s patient-specific cell models and cell culture media products with SBH’s cell-based assay services. As a result, SBH will be able to accelerate its efforts to generate drug response data for larger sets of patients that are clinically diagnosed with the same disease.
CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USA’s strength in stem cell culture media and manufacturing with Cellaria’s comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services.
CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its offerings to include a suite of stem cell services. The initiative advances Cellaria’s mission to provide more accurate patient and disease-specific cell models to help researchers focus and accelerate their research and discovery efforts.
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
CAMBRIDGE, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the release of two new ovarian cancer cell models and one breast cancer cell model. With these additions to its model library, Cellaria expands on its mission to provide researchers with more accurate models of the tumor, enabling more relevant and impactful research and accelerated discovery efforts.
The Official Platinum Co-Sponsors of Powering Precision Health 2016 are Quanterix and Cellaria Biosciences. Quanterix is renowned for its ground-breaking tools in high definition diagnostics for life science research, in-vitro diagnostics, companion diagnostics, and blood screening. Cellaria Biosciences creates breakthrough oncology models that ultimately lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure.
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.